The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.

Conexeu Sciences Inc. (NASDAQ: CNXU), a preclinical-stage biotech company, completed its 12-month P.R.O.O.F.™ preclinical study of its investigational CXU™ platform, which aims to address large-volume body tissue restoration in aesthetic medicine as demand for post-GLP-1 weight-loss volume restoration grows.

A Global Insurer Just Bought This Canadian Company’s Quantum-Risk Toolkit, and the Timing Is No Accident

Quantum Secure Encryption Corp. (CSE: QSE) secured its first major financial-services purchase order for its Quantum Preparedness Assessment platform from the Malaysian operations of a leading global insurance and asset-management group, marking a validation milestone as regulated enterprises prepare for quantum computing threats.